- Test-retest Study With [18F]FBB in Cardiac Amyloidosis — Recruiting • Phase I • Cardiology / Cardiovascular • NCT06790394.
- A study testing whether PET scans reliably detect amyloid buildup in hearts of patients with cardiac amyloidosis.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
This study is an open-label study to evaluate and characterize test-retest reliability of [18F]florbetaben PET in subjects with AL-CA and ATTR-CA compared to non-CA subjects. Quantification of the [18F]florbetaben parameters related to the deposition of amyloid in the heart (such as Myocardial Tracer Retention (MTR) or Retention Index (RI)), and the variability in these parameters after repeated imaging will be evaluated. Measurement of blood metabolites and comparison of invasive with non-invasive quantification of [18F]florbetaben uptake in the heart will be performed. Conditions: Cardiac Amyloidosis Interventions: Florbetaben F18 Lead Sponsor: Life…